Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 2857 to 2868 of 2868 entries
Sorted by: Best Match Show Resources per page
Detection of two dissimilar chronic wasting disease isolates in two captive Rocky Mountain elk (.

Prion

Nichols TA, Nicholson EM, Liu Y, Tao W, Spraker TR, Lavelle M, Fischer J, Kong Q, VerCauteren KC.
PMID: 34913829
Prion. 2021 Dec;15(1):207-215. doi: 10.1080/19336896.2021.1982333.

Chronic wasting disease (CWD) continues to spread in both wild and captive cervid herds in North America and has now been identified in wild reindeer and moose in Norway, Finland and Sweden. There is limited knowledge about the variety...

Cite
Nichols TA, Nicholson EM, Liu Y, et al. Detection of two dissimilar chronic wasting disease isolates in two captive Rocky Mountain elk (. Prion. 2021;15(1):207-215doi: 10.1080/19336896.2021.1982333.
Nichols, T. A., Nicholson, E. M., Liu, Y., Tao, W., Spraker, T. R., Lavelle, M., Fischer, J., Kong, Q., & VerCauteren, K. C. (2021). Detection of two dissimilar chronic wasting disease isolates in two captive Rocky Mountain elk (. Prion, 15(1), 207-215. https://doi.org/10.1080/19336896.2021.1982333
Nichols, Tracy A, et al. "Detection of two dissimilar chronic wasting disease isolates in two captive Rocky Mountain elk (." Prion vol. 15,1 (2021): 207-215. doi: https://doi.org/10.1080/19336896.2021.1982333
Nichols TA, Nicholson EM, Liu Y, Tao W, Spraker TR, Lavelle M, Fischer J, Kong Q, VerCauteren KC. Detection of two dissimilar chronic wasting disease isolates in two captive Rocky Mountain elk (. Prion. 2021 Dec;15(1):207-215. doi: 10.1080/19336896.2021.1982333. PMID: 34913829.
Copy Download .nbib Format: NLM
Experiences of the coronavirus disease-19 (COVID-19) pandemic from the perspectives of young people: Rapid qualitative study.

Public health in practice (Oxford, England)

Fisher H, Lambert H, Hickman M, Yardley L, Audrey S.
PMID: 34254057
Public Health Pract (Oxf). 2021 Nov;2:100162. doi: 10.1016/j.puhip.2021.100162. Epub 2021 Jul 08.

OBJECTIVES: Young people are considered at lower risk from coronavirus disease-19 (COVID-19). However, measures to limit the population health impact of the current COVID-19 pandemic have caused significant disruptions to their lives. The objective of this study was to...

Cite
Fisher H, Lambert H, Hickman M, et al. Experiences of the coronavirus disease-19 (COVID-19) pandemic from the perspectives of young people: Rapid qualitative study. Public Health Pract (Oxf). 2021;2:100162doi: 10.1016/j.puhip.2021.100162.
Fisher, H., Lambert, H., Hickman, M., Yardley, L., & Audrey, S. (2021). Experiences of the coronavirus disease-19 (COVID-19) pandemic from the perspectives of young people: Rapid qualitative study. Public health in practice (Oxford, England), 2100162. https://doi.org/10.1016/j.puhip.2021.100162
Fisher, Harriet, et al. "Experiences of the coronavirus disease-19 (COVID-19) pandemic from the perspectives of young people: Rapid qualitative study." Public health in practice (Oxford, England) vol. 2 (2021): 100162. doi: https://doi.org/10.1016/j.puhip.2021.100162
Fisher H, Lambert H, Hickman M, Yardley L, Audrey S. Experiences of the coronavirus disease-19 (COVID-19) pandemic from the perspectives of young people: Rapid qualitative study. Public Health Pract (Oxf). 2021 Nov;2:100162. doi: 10.1016/j.puhip.2021.100162. Epub 2021 Jul 08. PMID: 34254057; PMCID: PMC8264271.
Copy Download .nbib Format: NLM
Selinexor Enhances NK Cell Activation Against Malignant B Cells .

Frontiers in oncology

Fisher JG, Walker CJ, Doyle AD, Johnson PW, Forconi F, Cragg MS, Landesman Y, Khakoo SI, Blunt MD.
PMID: 34926302
Front Oncol. 2021 Dec 01;11:785635. doi: 10.3389/fonc.2021.785635. eCollection 2021.

Selinexor is an FDA approved selective inhibitor of the nuclear export protein exportin-1 (XPO1) and causes specific cancer cell death

Cite
Fisher JG, Walker CJ, Doyle AD, et al. Selinexor Enhances NK Cell Activation Against Malignant B Cells . Front Oncol. 2021;11:785635doi: 10.3389/fonc.2021.785635.
Fisher, J. G., Walker, C. J., Doyle, A. D., Johnson, P. W., Forconi, F., Cragg, M. S., Landesman, Y., Khakoo, S. I., & Blunt, M. D. (2021). Selinexor Enhances NK Cell Activation Against Malignant B Cells . Frontiers in oncology, 11785635. https://doi.org/10.3389/fonc.2021.785635
Fisher, Jack G, et al. "Selinexor Enhances NK Cell Activation Against Malignant B Cells ." Frontiers in oncology vol. 11 (2021): 785635. doi: https://doi.org/10.3389/fonc.2021.785635
Fisher JG, Walker CJ, Doyle AD, Johnson PW, Forconi F, Cragg MS, Landesman Y, Khakoo SI, Blunt MD. Selinexor Enhances NK Cell Activation Against Malignant B Cells . Front Oncol. 2021 Dec 01;11:785635. doi: 10.3389/fonc.2021.785635. eCollection 2021. PMID: 34926302; PMCID: PMC8672299.
Copy Download .nbib Format: NLM
Permeation Challenges of Drugs for Treatment of Neurological Tuberculosis and HIV and the Application of Magneto-Electric Nanoparticle Drug Delivery Systems.

Pharmaceutics

Mhambi S, Fisher D, Tchokonte MBT, Dube A.
PMID: 34575555
Pharmaceutics. 2021 Sep 15;13(9). doi: 10.3390/pharmaceutics13091479.

The anatomical structure of the brain at the blood-brain barrier (BBB) creates a limitation for the movement of drugs into the central nervous system (CNS). Drug delivery facilitated by magneto-electric nanoparticles (MENs) is a relatively new non-invasive approach for...

Cite
Mhambi S, Fisher D, Tchokonte MBT, et al. Permeation Challenges of Drugs for Treatment of Neurological Tuberculosis and HIV and the Application of Magneto-Electric Nanoparticle Drug Delivery Systems. Pharmaceutics. 2021;13(9)doi: 10.3390/pharmaceutics13091479.
Mhambi, S., Fisher, D., Tchokonte, M. B. T., & Dube, A. (2021). Permeation Challenges of Drugs for Treatment of Neurological Tuberculosis and HIV and the Application of Magneto-Electric Nanoparticle Drug Delivery Systems. Pharmaceutics, 13(9), . https://doi.org/10.3390/pharmaceutics13091479
Mhambi, Sinaye, et al. "Permeation Challenges of Drugs for Treatment of Neurological Tuberculosis and HIV and the Application of Magneto-Electric Nanoparticle Drug Delivery Systems." Pharmaceutics vol. 13,9 (2021). doi: https://doi.org/10.3390/pharmaceutics13091479
Mhambi S, Fisher D, Tchokonte MBT, Dube A. Permeation Challenges of Drugs for Treatment of Neurological Tuberculosis and HIV and the Application of Magneto-Electric Nanoparticle Drug Delivery Systems. Pharmaceutics. 2021 Sep 15;13(9). doi: 10.3390/pharmaceutics13091479. PMID: 34575555; PMCID: PMC8466684.
Copy Download .nbib Format: NLM
Survival and complications in patients with haemoglobin E thalassaemia in Sri Lanka: a prospective, longitudinal cohort study.

The Lancet. Global health

Premawardhena AP, Ediriweera DS, Sabouhanian A, Allen A, Rees D, de Silva S, Perera W, Katugaha N, Arambepola M, Yamashita RC, Mettananda S, Jiffry N, Mehta V, Cader R, Bandara D, St Pierre T, Muraca G, Fisher C, Kirubarajan A, Khan S, Allen S, Lamabadusuriya SP, Weatherall DJ, Olivieri NF.
PMID: 34843671
Lancet Glob Health. 2022 Jan;10(1):e134-e141. doi: 10.1016/S2214-109X(21)00446-0. Epub 2021 Nov 26.

BACKGROUND: Worldwide, haemoglobin E β-thalassaemia is the most common genotype of severe β-thalassaemia. The paucity of long-term data for this form of thalassaemia makes evidence-based management challenging. We did a long-term observational study to define factors associated with survival...

Cite
Premawardhena AP, Ediriweera DS, Sabouhanian A, et al. Survival and complications in patients with haemoglobin E thalassaemia in Sri Lanka: a prospective, longitudinal cohort study. Lancet Glob Health. 2021;10(1):e134-e141doi: 10.1016/S2214-109X(21)00446-0.
Premawardhena, A. P., Ediriweera, D. S., Sabouhanian, A., Allen, A., Rees, D., de Silva, S., Perera, W., Katugaha, N., Arambepola, M., Yamashita, R. C., Mettananda, S., Jiffry, N., Mehta, V., Cader, R., Bandara, D., St Pierre, T., Muraca, G., Fisher, C., Kirubarajan, A., Khan, S., Allen, S., Lamabadusuriya, S. P., Weatherall, D. J., & Olivieri, N. F. (2022). Survival and complications in patients with haemoglobin E thalassaemia in Sri Lanka: a prospective, longitudinal cohort study. The Lancet. Global health, 10(1), e134-e141. https://doi.org/10.1016/S2214-109X(21)00446-0
Premawardhena, Anuja P, et al. "Survival and complications in patients with haemoglobin E thalassaemia in Sri Lanka: a prospective, longitudinal cohort study." The Lancet. Global health vol. 10,1 (2022): e134-e141. doi: https://doi.org/10.1016/S2214-109X(21)00446-0
Premawardhena AP, Ediriweera DS, Sabouhanian A, Allen A, Rees D, de Silva S, Perera W, Katugaha N, Arambepola M, Yamashita RC, Mettananda S, Jiffry N, Mehta V, Cader R, Bandara D, St Pierre T, Muraca G, Fisher C, Kirubarajan A, Khan S, Allen S, Lamabadusuriya SP, Weatherall DJ, Olivieri NF. Survival and complications in patients with haemoglobin E thalassaemia in Sri Lanka: a prospective, longitudinal cohort study. Lancet Glob Health. 2022 Jan;10(1):e134-e141. doi: 10.1016/S2214-109X(21)00446-0. Epub 2021 Nov 26. PMID: 34843671.
Copy Download .nbib Format: NLM
Feasibility and Outcomes of a Standardized Management Protocol for Acute Exacerbation of Interstitial Lung Disease.

Lung

Adams CJ, Chohan K, Rozenberg D, Kavanagh J, Greyling G, Shapera S, Fisher JH.
PMID: 34347146
Lung. 2021 Aug;199(4):379-387. doi: 10.1007/s00408-021-00463-5. Epub 2021 Aug 04.

BACKGROUND AND OBJECTIVE: Despite the high mortality of acute exacerbations of interstitial lung disease (AE-ILD), there is minimal evidence to guide management decisions. We aimed to assess the feasibility and outcomes of a standardized management protocol for AE-ILD.METHODS: We...

Cite
Adams CJ, Chohan K, Rozenberg D, et al. Feasibility and Outcomes of a Standardized Management Protocol for Acute Exacerbation of Interstitial Lung Disease. Lung. 2021;199(4):379-387doi: 10.1007/s00408-021-00463-5.
Adams, C. J., Chohan, K., Rozenberg, D., Kavanagh, J., Greyling, G., Shapera, S., & Fisher, J. H. (2021). Feasibility and Outcomes of a Standardized Management Protocol for Acute Exacerbation of Interstitial Lung Disease. Lung, 199(4), 379-387. https://doi.org/10.1007/s00408-021-00463-5
Adams, Colin J, et al. "Feasibility and Outcomes of a Standardized Management Protocol for Acute Exacerbation of Interstitial Lung Disease." Lung vol. 199,4 (2021): 379-387. doi: https://doi.org/10.1007/s00408-021-00463-5
Adams CJ, Chohan K, Rozenberg D, Kavanagh J, Greyling G, Shapera S, Fisher JH. Feasibility and Outcomes of a Standardized Management Protocol for Acute Exacerbation of Interstitial Lung Disease. Lung. 2021 Aug;199(4):379-387. doi: 10.1007/s00408-021-00463-5. Epub 2021 Aug 04. PMID: 34347146.
Copy Download .nbib Format: NLM
Splitting of the Alveolar Process of the Lower Jaw.

The Dental register

Fisher GJ.
PMID: 33694546
Dent Regist. 1858 Dec;12(2):187-189.

No abstract available.

Cite
Fisher GJ. Splitting of the Alveolar Process of the Lower Jaw. Dent Regist. 1858;12(2):187-189
Fisher, G. J. (1858). Splitting of the Alveolar Process of the Lower Jaw. The Dental register, 12(2), 187-189.
Fisher, G J. "Splitting of the Alveolar Process of the Lower Jaw." The Dental register vol. 12,2 (1858): 187-189.
Fisher GJ. Splitting of the Alveolar Process of the Lower Jaw. Dent Regist. 1858 Dec;12(2):187-189. PMID: 33694546; PMCID: PMC6850828.
Copy Download .nbib Format: NLM
Tandem Therapeutic Plasma Exchange Reduces Continuous Renal Replacement Therapy Downtime.

Blood purification

Foglia MJ, Pelletier JH, Bayir H, Fleck A, Konyk L, McSteen C, Fisher D, Fuhrman DY.
PMID: 34515068
Blood Purif. 2021 Sep 01;1-8. doi: 10.1159/000518348. Epub 2021 Sep 01.

INTRODUCTION: Continuous renal replacement therapy (CRRT) has become a primary treatment of severe acute kidney injury in children admitted to the intensive care unit. CRRT "downtime" (when the circuit is not active) can represent a significant portion of the...

Cite
Foglia MJ, Pelletier JH, Bayir H, et al. Tandem Therapeutic Plasma Exchange Reduces Continuous Renal Replacement Therapy Downtime. Blood Purif. 2021;1-8doi: 10.1159/000518348.
Foglia, M. J., Pelletier, J. H., Bayir, H., Fleck, A., Konyk, L., McSteen, C., Fisher, D., & Fuhrman, D. Y. (2021). Tandem Therapeutic Plasma Exchange Reduces Continuous Renal Replacement Therapy Downtime. Blood purification, 1-8. https://doi.org/10.1159/000518348
Foglia, Matthew J, et al. "Tandem Therapeutic Plasma Exchange Reduces Continuous Renal Replacement Therapy Downtime." Blood purification vol. (2021): 1-8. doi: https://doi.org/10.1159/000518348
Foglia MJ, Pelletier JH, Bayir H, Fleck A, Konyk L, McSteen C, Fisher D, Fuhrman DY. Tandem Therapeutic Plasma Exchange Reduces Continuous Renal Replacement Therapy Downtime. Blood Purif. 2021 Sep 01;1-8. doi: 10.1159/000518348. Epub 2021 Sep 01. PMID: 34515068.
Copy Download .nbib Format: NLM
Payload Delivery: Engineering Immune Cells to Disrupt the Tumour Microenvironment.

Cancers

Fowler D, Nattress C, Navarrete AS, Barisa M, Fisher J.
PMID: 34885108
Cancers (Basel). 2021 Nov 29;13(23). doi: 10.3390/cancers13236000.

Although chimeric antigen receptor (CAR) T cells have shown impressive clinical success against haematological malignancies such as B cell lymphoma and acute lymphoblastic leukaemia, their efficacy against non-haematological solid malignancies has been largely disappointing. Solid tumours pose many additional...

Cite
Fowler D, Nattress C, Navarrete AS, et al. Payload Delivery: Engineering Immune Cells to Disrupt the Tumour Microenvironment. Cancers (Basel). 2021;13(23)doi: 10.3390/cancers13236000.
Fowler, D., Nattress, C., Navarrete, A. S., Barisa, M., & Fisher, J. (2021). Payload Delivery: Engineering Immune Cells to Disrupt the Tumour Microenvironment. Cancers, 13(23), . https://doi.org/10.3390/cancers13236000
Fowler, Daniel, et al. "Payload Delivery: Engineering Immune Cells to Disrupt the Tumour Microenvironment." Cancers vol. 13,23 (2021). doi: https://doi.org/10.3390/cancers13236000
Fowler D, Nattress C, Navarrete AS, Barisa M, Fisher J. Payload Delivery: Engineering Immune Cells to Disrupt the Tumour Microenvironment. Cancers (Basel). 2021 Nov 29;13(23). doi: 10.3390/cancers13236000. PMID: 34885108; PMCID: PMC8657158.
Copy Download .nbib Format: NLM
Integrate mechanistic evidence from new approach methodologies (NAMs) into a read-across assessment to characterise trends in shared mode of action.

Toxicology in vitro : an international journal published in association with BIBRA

Escher SE, Aguayo-Orozco A, Benfenati E, Bitsch A, Braunbeck T, Brotzmann K, Bois F, van der Burg B, Castel J, Exner T, Gadaleta D, Gardner I, Goldmann D, Hatley O, Golbamaki N, Graepel R, Jennings P, Limonciel A, Long A, Maclennan R, Mombelli E, Norinder U, Jain S, Capinha LS, Taboureau OT, Tolosa L, Vrijenhoek NG, van Vugt-Lussenburg BMA, Walker P, van de Water B, Wehr M, White A, Zdrazil B, Fisher C.
PMID: 34757180
Toxicol In Vitro. 2022 Mar;79:105269. doi: 10.1016/j.tiv.2021.105269. Epub 2021 Oct 29.

Read-across approaches often remain inconclusive as they do not provide sufficient evidence on a common mode of action across the category members. This read-across case study on thirteen, structurally similar, branched aliphatic carboxylic acids investigates the concept of using...

Cite
Escher SE, Aguayo-Orozco A, Benfenati E, et al. Integrate mechanistic evidence from new approach methodologies (NAMs) into a read-across assessment to characterise trends in shared mode of action. Toxicol In Vitro. 2021;79:105269doi: 10.1016/j.tiv.2021.105269.
Escher, S. E., Aguayo-Orozco, A., Benfenati, E., Bitsch, A., Braunbeck, T., Brotzmann, K., Bois, F., van der Burg, B., Castel, J., Exner, T., Gadaleta, D., Gardner, I., Goldmann, D., Hatley, O., Golbamaki, N., Graepel, R., Jennings, P., Limonciel, A., Long, A., Maclennan, R., Mombelli, E., Norinder, U., Jain, S., Capinha, L. S., Taboureau, O. T., Tolosa, L., Vrijenhoek, N. G., van Vugt-Lussenburg, B. M. A., Walker, P., van de Water, B., Wehr, M., White, A., Zdrazil, B., & Fisher, C. (2022). Integrate mechanistic evidence from new approach methodologies (NAMs) into a read-across assessment to characterise trends in shared mode of action. Toxicology in vitro : an international journal published in association with BIBRA, 79105269. https://doi.org/10.1016/j.tiv.2021.105269
Escher, Sylvia E, et al. "Integrate mechanistic evidence from new approach methodologies (NAMs) into a read-across assessment to characterise trends in shared mode of action." Toxicology in vitro : an international journal published in association with BIBRA vol. 79 (2022): 105269. doi: https://doi.org/10.1016/j.tiv.2021.105269
Escher SE, Aguayo-Orozco A, Benfenati E, Bitsch A, Braunbeck T, Brotzmann K, Bois F, van der Burg B, Castel J, Exner T, Gadaleta D, Gardner I, Goldmann D, Hatley O, Golbamaki N, Graepel R, Jennings P, Limonciel A, Long A, Maclennan R, Mombelli E, Norinder U, Jain S, Capinha LS, Taboureau OT, Tolosa L, Vrijenhoek NG, van Vugt-Lussenburg BMA, Walker P, van de Water B, Wehr M, White A, Zdrazil B, Fisher C. Integrate mechanistic evidence from new approach methodologies (NAMs) into a read-across assessment to characterise trends in shared mode of action. Toxicol In Vitro. 2022 Mar;79:105269. doi: 10.1016/j.tiv.2021.105269. Epub 2021 Oct 29. PMID: 34757180.
Copy Download .nbib Format: NLM
Building a pipeline of training for behavioral diabetes researchers and clinicians: a call for national dialogue.

de Groot M, Fisher L.
UIID-AD: 2695
2011;11:503-10. doi: 10.1007/s11892-011-0231-x.

In the context of a diabetes epidemic and health care workforce crisis in the United States, a national dialogue is needed to identify the pathways and mechanisms for training a cohort of behavioral diabetes researchers and clinicians. Over the...

Cite
de Groot M, Fisher L. Building a pipeline of training for behavioral diabetes researchers and clinicians: a call for national dialogue. 2011;11:503-10doi: 10.1007/s11892-011-0231-x.
de Groot, M., & Fisher, L. (2011). Building a pipeline of training for behavioral diabetes researchers and clinicians: a call for national dialogue. 11503-10. https://doi.org/10.1007/s11892-011-0231-x
de Groot, M, and Fisher, L. "Building a pipeline of training for behavioral diabetes researchers and clinicians: a call for national dialogue." vol. 11 (2011): 503-10. doi: https://doi.org/10.1007/s11892-011-0231-x
de Groot M, Fisher L. Building a pipeline of training for behavioral diabetes researchers and clinicians: a call for national dialogue. 2011;11:503-10. doi: 10.1007/s11892-011-0231-x. UIID-AD: 2695.
Copy Download .nbib Format: NLM
Differences in STEM doctoral publication by ethnicity, gender and academic field at a large public research university.

Smith A, Mendoza-Denton R, Patt C, Fisher A, Eppig A, Young I, Richards MA.
UIID-AD: 4388
2017; doi: 10.1371/journal.pone.0174296.

Two independent surveys of PhD students in STEM fields at the University of California, Berkeley, indicate that underrepresented minorities (URMs) publish at significantly lower rates than non-URM males, placing the former at a significant disadvantage as they compete for...

Cite
Smith A, Mendoza-Denton R, Patt C, et al. Differences in STEM doctoral publication by ethnicity, gender and academic field at a large public research university. 2017;doi: 10.1371/journal.pone.0174296.
Smith, A., Mendoza-Denton, R., Patt, C., Fisher, A., Eppig, A., Young, I., & Richards, M. A. (2017). Differences in STEM doctoral publication by ethnicity, gender and academic field at a large public research university. . https://doi.org/10.1371/journal.pone.0174296
Smith, A, et al. "Differences in STEM doctoral publication by ethnicity, gender and academic field at a large public research university." vol. (2017). doi: https://doi.org/10.1371/journal.pone.0174296
Smith A, Mendoza-Denton R, Patt C, Fisher A, Eppig A, Young I, Richards MA. Differences in STEM doctoral publication by ethnicity, gender and academic field at a large public research university. 2017; doi: 10.1371/journal.pone.0174296. UIID-AD: 4388.
Copy Download .nbib Format: NLM
Showing 2857 to 2868 of 2868 entries